Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

被引：16

作者：

Jabbour, Elias ^{[1
]}

Aldoss, Ibrahim ^{[2
]}

Fleming, Shaun ^{[3
]}

Bajel, Ashish ^{[4
,5
]}

Cannell, Paul ^{[6
]}

Bruggemann, Monika ^{[7
]}

Zugmaier, Gerhard ^{[8
]}

Morris, Joan ^{[9
]}

Chen, Yuqi ^{[9
]}

Powar, Sonny ^{[10
]}

Wong, Hansen ^{[11
]}

Steffen, Bjorn ^{[12
]}

Kantarjian, Hagop ^{[1
]}

Goekbuget, Nicola ^{[13
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] City Hope Natl Med Ctr, Duarte, CA USA

[3] Alfred, Melbourne, Vic, Australia

[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic, Australia

[6] Fiona Stanley Hosp, Murdoch, WA, Australia

[7] Univ Med Ctr Schleswig Holstein, Kiel, Germany

[8] Amgen Res GmbH, Munich, Germany

[9] Amgen Inc, Thousand Oaks, CA 91320 USA

[10] Amgen Inc, Uxbridge, Middx, England

[11] Amgen Inc, San Francisco, CA USA

[12] Goethe Univ Hosp, Dept Med 2, Hematol Oncol, Frankfurt, Germany

[13] Goethe Univ, Univ Hosp, Dept Med 2, Frankfurt, Germany

来源：

关键词：

D O I：

10.1182/blood-2022-156080

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6134 / 6136

页数：3